Hopeful for Good data early 2025!!!!

$Azitra (AZTR.US)$ Key updates include a $10 million follow-on offering, the dosing of the first Netherton syndrome patient with ATR-12, an IND clearance and Fast Track designation for ATR-04, and new patent approvals. Upcoming milestones in early 2025 include safety data for ATR-12 and a Phase 1/2 trial for ATR-04 targeting EGFR inhibitor rash. Financially, Azitra reported no revenue for Q3 2024, with increased R&D and G&A expenses totaling $2.9 million, and a net loss of $1 million. Cash reserves stood at $7.3 million as of September 30, 2024.